Astrazeneca P L C (AZN)

(A Top Pick May 10/17, Up 16%) It's a diversified biopharma out of the UK. Surprised many by annoucning phase 2 drug trial in lung cancer--a frontrunner in this space. Their main drivers is their immunotherapy business. A great growth profile in the industry, but need to execute on a few of these trials in the next 6-12 months. Own it with BMY-N and MRK-N and not alone.

Has an impressive line of new products that should hit the market over the next 10 years, in cancer, diabetes and Alzheimer’s. They have underperformed for the last several years, and now is starting to turn the corner. Dividend yield of 4.28%. (Analysts’ Price Target is $38.)

It is rare he has puts on in his fund, but he does on this one. They have declining revenues, but a huge amount of data coming out about the next 12 to 18 months. We have seen the tip of the iceberg. He still likes it. It is not terribly expensive and has a high dividend. Own it with others for diversification. M&A would not surprise him in big pharma soon.

A diversified pharmaceutical, sort of shifting their business away from traditional fields. They are in decline right now on revenues. You want to be holding this along with Merck and Bristol-Myers. They have a very key study coming out, taking an immuno oncology drug and combining it with another immuno oncology drug. That is going to be a very key catalyst. Dividend yield of 4.5%. (Analysts’ price target is $34.)

Pfizer failed to acquire this company and the stock has dropped a lot. This trades at 14X earnings and has a great dividend yield and a great cash flow yield. Not expensive. Have some great things in their pipeline in the next little while, which will help the company out. Healthcare is a nice defensive area to be in if you are really worried about the stock market. (See Top Picks.)